Remodulin Journal Ad, Booklet Prompt FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
United Therapeutics' promotional materials make misleading comparisons between Remodulin and GlaxoSmithKline's Flolan, FDA's ad review division says. The company says it discontinued the ads and requested doctors stop using the "Frequently Asked Questions" booklet in July 2004.
You may also be interested in...
United Therapeutics’ Remodulin Approved For Transition From GSK’s Flolan
The expanded indication completes Remodulin’s accelerated approval requirements.
United Therapeutics’ Remodulin Approved For Transition From GSK’s Flolan
The expanded indication completes Remodulin’s accelerated approval requirements.
Schering, GSK Reviewing Levitra Promotions After FDA Cites 15-Second TV Ad
Commercial for Levitra does not qualify as "reminder ad" because it includes effectiveness claims, agency says in an ad division letter. Acting Commissioner Crawford has expressed a desire to crack down on DTC ads in the erectile dysfunction category. Levitra is one of four products cited by the agency in letters posted over a two-day period.